{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:04:46Z","timestamp":1780985086527,"version":"3.54.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    The bedaquiline (B), pretomanid (Pa), and linezolid (L) (BPaL) regimen is highly effective for drug-resistant tuberculosis (TB) but is limited by linezolid-associated toxicities, including myelosuppression and peripheral neuropathy. We evaluated omadacycline as a representative tetracycline-class protein synthesis inhibitor (PSI) to assess whether it can contribute functional activity within a BPa backbone. Omadacycline exhibited a minimum inhibitory concentration (MIC) of 2\u20134 \u03bcg\/mL against\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    H37Rv and 10\u201348 \u03bcg\/mL against representatives of four global clades. Daily media replacement reduced the MIC against H37Rv to 0.29 \u03bcg\/mL, suggesting antibiotic instability may underestimate\n                    <jats:italic>in vitro<\/jats:italic>\n                    potency.\n                    <jats:italic>In vivo<\/jats:italic>\n                    , subcutaneous administration of omadacycline (15 mg\/kg) in BALB\/c mice, yielding plasma exposures within the range of those reported for the approved 300-mg oral human dose, led to a 0.7-log\n                    <jats:sub>10<\/jats:sub>\n                    reduction in lung colony-forming units (CFU) in both acute and chronic TB models. In combination therapy, 10-week treatment with BPa plus either linezolid (BPaL) or omadacycline (BPaO) further reduced lung CFU by \u223c1 log\n                    <jats:sub>10<\/jats:sub>\n                    relative to BPa alone, demonstrating the contribution of a PSI to regimen efficacy. Notably, BPaO and BPaL reduced relapse rates after 10 weeks of treatment to 43 and 23%, respectively, compared to 100% relapse in the BPa-only group. Together, these findings provide proof-of-concept evidence that omadacycline has\n                    <jats:italic>in vivo<\/jats:italic>\n                    antitubercular activity, achieves clinically relevant exposures, and can contribute functional PSI activity in combination regimens however, these results do not establish clinical equivalence with linezolid and support further evaluation of tetracycline-class agents in TB therapy.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2026.1789810","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:43:39Z","timestamp":1780983819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro and in vivo activity of omadacycline against Mycobacterium tuberculosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Shahebraj","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Nikolic","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojie","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akil","family":"Hossain","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallique","family":"Qader","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghyun","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Franzblau","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri S.","family":"Shetye","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"R96190","DOI":"10.7554\/eLife.96190","article-title":"A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides.","volume":"13","author":"Ali","year":"2024","journal-title":"Elife"},{"key":"B2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/antibiotics9120905","article-title":"Use of oral tetracyclines in the treatment of adult patients with community-acquired bacterial pneumonia: A literature review on the often-overlooked antibiotic class.","volume":"9","author":"Bidell","year":"2020","journal-title":"Antibiotics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7399\/fh.11133","article-title":"Optic neuropathy associated with linezolid: Systematic review of cases.","volume":"43","author":"Brandariz-N\u00fa\u00f1ez","year":"2019","journal-title":"Farm. Hosp."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2147\/IDR.S171352","article-title":"Omadacycline: A novel aminomethylcycline.","volume":"12","author":"Burgos","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"B5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/molbev\/msz214","article-title":"The genetic background modulates the evolution of fluoroquinolone-resistance in Mycobacterium tuberculosis.","volume":"37","author":"Castro","year":"2020","journal-title":"Mol. Biol. Evol."},{"key":"B6","volume-title":"Biosafety in Microbiological and Biomedical Laboratories","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses.","volume":"77","author":"Chapagain","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/FTD.0000000000001308","article-title":"Development of a UHPLC-MS\/MS method for the determination of omadacycline in human plasma.","volume":"47","author":"Chen","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"B9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-1-4939-2450-9_17","article-title":"Microplate Alamar Blue Assay (MABA) and Low Oxygen Recovery Assay (LORA) for Mycobacterium tuberculosis.","volume":"1285","author":"Cho","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-Linezolid regimens for drug-resistant tuberculosis.","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis.","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1024608","DOI":"10.3389\/fphar.2022.1024608","article-title":"Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy.","volume":"13","author":"Deshpande","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.","volume":"178","author":"Dietze","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1972","DOI":"10.1128\/AAC.01972-19","article-title":"In Vitro and intracellular activities of omadacycline against Legionella pneumophila.","volume":"64","author":"Dubois","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1749-6632.1948.tb27262.x","article-title":"Aureomycin; a product of the continuing search for new antibiotics.","volume":"51","author":"Duggar","year":"1948","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/ph12020063","article-title":"Omadacycline: A newly approved antibacterial from the class of tetracyclines.","volume":"12","author":"Dur\u00e3es","year":"2019","journal-title":"Pharmaceuticals"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3201\/eid0811.020125","article-title":"Global distribution of Mycobacterium tuberculosis spoligotypes.","volume":"8","author":"Filliol","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/cid\/ciz394","article-title":"Omadacycline: A modernized tetracycline.","volume":"69","author":"Gallagher","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1128\/AAC.04054-14","article-title":"The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.","volume":"59","author":"Gao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/srep01146","article-title":"Efficacy of post exposure administration of doxycycline in a murine model of inhalational melioidosis.","volume":"3","author":"Gelhaus","year":"2013","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2479","DOI":"10.1128\/AAC.02479-19","article-title":"Tissue distribution of doxycycline in animal models of tuberculosis.","volume":"64","author":"Gengenbacher","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: Summary of clinical experience.","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1086\/520547","article-title":"Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.","volume":"196","author":"Heine","year":"2007","journal-title":"J. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance.","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis.","volume":"367","author":"Lee","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B26","volume-title":"A Color Atlas of Comparative Pathology of Pulmonary Tuberculosis","author":"Leong","year":"2010"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e02368-16","DOI":"10.1128\/AAC.02368-16","article-title":"In Vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model.","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1784","DOI":"10.1128\/AAC.01784-16","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-Omadacycline in rats.","volume":"61","author":"Lin","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102592","DOI":"10.1016\/j.tube.2024.102592","article-title":"Development of tetracycline analogues with increased aqueous stability for the treatment of mycobacterial infections.","volume":"150","author":"Liu","year":"2025","journal-title":"Tuberculosis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"ofad335","DOI":"10.1093\/ofid\/ofad335","article-title":"Long-term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections.","volume":"10","author":"Mingora","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4103\/1995-7645.329004","article-title":"Nix-Tb and ZeNix trials: Paving the way for shorter regimens for drug-resistant tuberculosis.","volume":"14","author":"Mishra","year":"2021","journal-title":"Asian Pacific J. Trop. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06354.x","article-title":"The history of the tetracyclines.","volume":"1241","author":"Nelson","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): An open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic.","volume":"69","author":"Opal","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12864-019-5615-3","article-title":"Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals lineage-specific associations with drug resistance.","volume":"20","author":"Oppong","year":"2019","journal-title":"BMC Genom."},{"key":"B36","doi-asserted-by":"publisher","first-page":"105059","DOI":"10.1016\/j.cmicom.2025.105059","article-title":"Tetracyclines, the old and the new: A narrative review.","volume":"2","author":"Pearson","year":"2025","journal-title":"CMI Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions.","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0066522","DOI":"10.1128\/msphere.00665-22","article-title":"Efficacy of omadacycline-containing regimen in a mouse model of pulmonary Mycobacteroides abscessus disease.","volume":"8","author":"Rimal","year":"2023","journal-title":"mSphere"},{"key":"B39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4046\/trd.2022.0148","article-title":"Improving tuberculosis medication adherence: The potential of integrating digital technology and health belief model.","volume":"86","author":"Sazali","year":"2023","journal-title":"Tuberc. Respir. Dis."},{"key":"B40","first-page":"214","article-title":"[Stability of Mic values from tetracyclines in different media (author\u2019s transl)].","volume":"6","author":"Sch\u00e4,fer","year":"1978","journal-title":"Immun. Infekt."},{"key":"B41","doi-asserted-by":"publisher","first-page":"102269","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria.","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0159421","DOI":"10.1128\/spectrum.01594-21","article-title":"Mycobacterium tuberculosis lineages associated with mutations and drug resistance in isolates from India.","volume":"10","author":"Shanmugam","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e01703","DOI":"10.1016\/j.idcr.2023.e01703","article-title":"Omadacycline for the treatment of Mycobacterium abscessus infections: Case series and review of the literature.","volume":"31","author":"Siddiqa","year":"2023","journal-title":"IDCases"},{"key":"B44","doi-asserted-by":"publisher","first-page":"139127","DOI":"10.1155\/2012\/139127","article-title":"The tuberculous granuloma: An unsuccessful host defence mechanism providing a safety shelter for the bacteria?","volume":"2012","author":"Silva Miranda","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0108023","DOI":"10.1128\/aac.01080-23","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model.","volume":"68","author":"Singh","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"106847","DOI":"10.1016\/j.ijantimicag.2023.106847","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.","volume":"62","author":"Singh","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1164\/art.1949.59.2.221","article-title":"Tuberculostatic activity of aureomycin in vitro and in vivo.","volume":"59","author":"Steenken","year":"1949","journal-title":"Am. Rev. Tuberc."},{"key":"B49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1749-6632.1950.tb42164.x","article-title":"The tuberculostatic action of terramycin in vitro and in the experimental animal.","volume":"53","author":"Steenken","year":"1950","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40268-025-00531-8","article-title":"Omadacycline pharmacokinetics: Characteristics, contributing factors, and clinical significance.","volume":"25","author":"Sun","year":"2025","journal-title":"Drugs R. D."},{"key":"B51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/AAC.01691-15","article-title":"Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis.","volume":"60","author":"Tasneen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.","volume":"49","author":"Tyagi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: A turning point.","volume":"130","author":"Vanino","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1164\/rccm.201110-1769OC","article-title":"Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.","volume":"185","author":"Walker","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1380312","DOI":"10.3389\/fcimb.2024.1380312","article-title":"Efficacy of omadacycline in the treatment of Legionella pneumonia: A case report.","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e00021-19","DOI":"10.1128\/AAC.00021-19","article-title":"Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis.","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/03601230903404556","article-title":"Hydrolysis and photolysis of oxytetracycline in aqueous solution.","volume":"45","author":"Xuan","year":"2010","journal-title":"J. Environ. Sci. Health B"},{"key":"B58","doi-asserted-by":"publisher","first-page":"11981","DOI":"10.1073\/pnas.1206210109","article-title":"Stabilization of vaccines and antibiotics in silk and eliminating the cold chain.","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1789810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:43:40Z","timestamp":1780983820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1789810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":58,"alternative-id":["10.3389\/fmicb.2026.1789810"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1789810","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1789810"}}